SCHEMBL6018142

SCHEMBL6018142

COC(=O)c1ccc(C)c2ncccc12

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.73
PSMD14 O00487 2/20 0.57
MAP2K1 Q02750 1/20 0.54
SLC40A1 Q9NP59 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
PDE4A P27815 2/20 0.47
PDE4B Q07343 2/20 0.47
PDE4C Q08493 2/20 0.47
PDE4D Q08499 2/20 0.47
KDM4A O75164 2/20 0.46
KDM4C Q9H3R0 2/20 0.46
KDM6B O15054 1/20 0.46
KDM6A O15550 1/20 0.46
TET3 O43151 1/20 0.46
KDM4B O94953 1/20 0.46
KDM5C P41229 1/20 0.46
KDM4D Q6B0I6 1/20 0.46
TET2 Q6N021 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21878477 0.88 KDM4E (0.64) KDM4EPSMD14MAP2K1SLC40A1PDE4A
SCHEMBL19642874 0.88 PSMD14 (0.69) KDM4EPSMD14MAP2K1SLC40A1MEN1
SCHEMBL23714061 0.85 KDM4E (0.56) KDM4EMEN1KMT2ASMN1; SMN2KDM4A
SCHEMBL6068105 0.84 KDM4E (1.00) KDM4EPSMD14MAP2K1KDM4AKDM4C
SCHEMBL30744938 0.84 KDM4E (1.00) KDM4EPSMD14MAP2K1KDM4AKDM4C
SCHEMBL9944372 0.84 KDM4E (0.52) KDM4EPSMD14MEN1KMT2ASMN1; SMN2
SCHEMBL15758767 0.83 KDM4E (0.71) KDM4EPSMD14MAP2K1SLC40A1MEN1
SCHEMBL3503003 0.83 KDM4E (0.71) KDM4EPSMD14MAP2K1SLC40A1SMN1; SMN2
SCHEMBL20952065 0.83 KDM4E (0.77) KDM4EPSMD14MAP2K1SLC40A1MEN1
SCHEMBL17113034 0.83 KDM4E (0.71) KDM4EPSMD14MAP2K1SLC40A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846291-B2 Resist composition, method of forming resist pattern, and new compound TOKYO OHKA KOGYO CO. LTD. (JP) 2014-09-30 US disclosed
US-20120148955-A1 RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, AND NEW COMPOUND TOKYO OHKA KOGYO CO., LTD. (JP) 2012-06-14 US disclosed
US-7098215-B2 Nitrogenous compounds and antiviral drugs containing the same KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) 2006-08-29 US disclosed
US-20040092556-A1 Nitrogenous compounds and antiviral drugs containing the same KUREHA CORPORATION (JP) 2004-05-13 US disclosed
EP-1273571-A1 NITROGENOUS COMPOUNDS AND ANTIVIRAL DRUGS CONTAINING THE SAME Kureha Chemical Industry Co., Ltd. (JP) 2003-01-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092556-A1 Nitrogenous compounds and antiviral drugs containing the same NSUN2, ZC3HAV1L, PNP KDM4E 3110/4885PSMD14 1882/4885MAP2K1 3244/4885
US-20120148955-A1 RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, AND NEW COMPOUND C1R, SLC11A2, RER1 KDM4E 4730/4885PSMD14 4089/4885MAP2K1 2941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.